Blog
RSS FeedPosted by Michael Wonder on 11 Sep 2015
Updated label for Daklinza (daclatasvir) for the 12-week treatment of non-cirrhotic patients with chronic hepatitis C genotype 3 approved by the European Commission
10 September 2015 - Bristol-Myers Squibb Company announced today that the European Commission has approved an updated label for Daklinza for ...
Posted by Michael Wonder on 10 Sep 2015
Santhera receives European marketing authorisation for Raxone in Leber's hereditary optic neuropathy (LHON)
9 September 2015 - Santhera Pharmaceuticals announces the European Commission (EC) has granted marketing authorisation for Raxone as the first approved ...
Posted by Michael Wonder on 04 Sep 2015
Novartis receives EU approval for Farydak, the first in its class of anticancer agents approved for patients with multiple myeloma
4 September 2015 - Novartis announced today that the European Commission has approved Farydak (panobinostat, previously known as LBH589) capsules, in ...
Posted by Michael Wonder on 04 Sep 2015
Novartis wins EU approval for multiple myeloma drug Farydak
4 September 2015 - Novartis AG said on Friday it received European Union approval for Farydak, a treatment for multiple myeloma ...
Posted by Michael Wonder on 03 Sep 2015
ALK obtains European approval for its house dust mite sublingual allergy immunotherapy tablet against allergic rhinitis and allergic asthma
31 August 2015 - ALK today announced that it has successfully completed the registration procedure for its house dust mite (HDM) ...
Posted by Michael Wonder on 03 Sep 2015
Novartis receives EU approval for new Revolade use as first-in-class therapy for patients with severe aplastic anemia
2 September 2015 - Novartis announced today that the European Commission has approved Revolade (eltrombopag olamine) for the treatment of adults ...
Posted by Michael Wonder on 01 Sep 2015
Novartis receives EU approval for Tafinlar and Mekinist, first combination approved for patients with aggressive form of melanoma
1 September 2015 - Novartis today announced that the European Commission has approved the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) ...
Posted by Michael Wonder on 01 Sep 2015
European Commission grants marketing authorisation for Strensiq (asfotase alfa) for the treatment of patients with paediatric-onset hypophosphatasia (HPP)
1 September 2015 - Alexion Pharmaceuticals, Inc. announced today that the European Commission has approved Strensiq (asfotase alfa) for long-term enzyme ...
Posted by Michael Wonder on 01 Sep 2015
European Commission grants marketing authorisation for Kanuma (sebelipase alfa) for the treatment of patients of all ages with lysosomal acid lipase deficiency (LAL-D)
1 September 2015 - Alexion Pharmaceuticals, Inc. announced today that the European Commission (EC) has approved Kanuma (sebelipase alfa) for long-term ...